Spero Therapeutics Reports the US FDA’s IND Clearance of SPR206 for the Treatment of MDR Gram-Negative Bacterial Infections
Shots:
- The US FDA has cleared Spero’s IND application to develop SPR206, next-generation polymyxin therapy, in P-II trial SPR206 to treat hospital-acquired & ventilator-associated bacterial pneumonia (HABP/VABP) caused by MDR gram-negative bacterial infections
- The P-II trial will assess the safety, tolerability, efficacy & PK of SPR206 combined with selected antibiotics for treating HABP or VABP patients (n=60)
- Additionally, Pfizer holds the global (excl. US & Asia) rights for developing, manufacturing & commercializing SPR206. Spero will receive ~$80M as development & sales milestones plus high single-digit to low double-digit net sales-based royalties in these regions
Ref: Spero Therapeutics | Image: Spero Therapeutics
Related Post:- GSK Entered into an Exclusive License Agreement with Spero Therapeutics for Tebipenem HBr to Treat Urinary Tract Infections
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
